The in vitro Evaluation of the Activity of COVID-19 Antiviral Drugs Against Adenovirus

References

• King D, Johnson B, Miller D, et al. Adenovirus-associated epidemic keratoconjunctivitis outbreaks—Four States 2008–2010. Morb Mortal Wkly Rep. 2013;62:637–641.
   PubMed Web of Science ®Google Scholar
• Garcia-Zalisnak D, Rapuano C, Sheppard JD, Davis AR. Adenovirus ocular infections: prevalence, pathology, pitfalls, and practical pointers. Eye Contact Lens. 2018;44:S1–S7. doi:10.1097/ICL.0000000000000226
   Web of Science ®Google Scholar
• Hoffman J. Adenovirus: ocular manifestations. Community Eye Health. 2020;33:73–75.
   Google Scholar
• Malin JJ, Suárez I, Priesner V, Fätkenheuer G, Rybniker J. Remdesivir against COVID-19 and other viral diseases. Clin Microbiol Rev. 2021;34:e00162–20.
   Web of Science ®Google Scholar
• Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2001;323:264–268. doi:10.1016/j.bbrc.2004.08.085
   Web of Science ®Google Scholar
• Jans DA, Wagstaff KM. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2? Biochem Biophys Res Commun. 2021;538:163–172. doi:10.1016/j.bbrc.2020.10.042
   Web of Science ®Google Scholar
• King CR, Tessier TM, Dodge MJ, Weinberg JB, Mymryk JS. Inhibition of human adenovirus replication by the importin α/β1 nuclear import inhibitor ivermectin. J Virol. 2020;94:e00710–20. doi:10.1128/JVI.00710-20
   Web of Science ®Google Scholar
• Nojomi M, Yassin Z, Keyvani H, et al. Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial. BMC Infect Dis. 2020;20:954. doi:10.1186/s12879-020-05698-w
   PubMed Web of Science ®Google Scholar
• Shi L, Xiong H, He J, et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol. 2007;152:1447–1455. doi:10.1007/s00705-007-0974-5
   PubMed Web of Science ®Google Scholar
• Zhou X, Robinson CM, Rajaiya J, et al. Analysis of human adenovirus type 19 associated with epidemic keratoconjunctivitis and its reclassification as adenovirus type 64. Invest Ophthalmol Vis Sci. 2012;53:2804–2811. doi:10.1167/iovs.12-9656
   PubMed Web of Science ®Google Scholar
• Gordon YJ, Romanowski EG, Araullo-Cruz T, et al. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2ʹ-nor-Cyclic GMP on different ocular adenoviral serotypes in vitro. Antiviral Res. 1991;16:11–16. doi:10.1016/0166-3542(91)90054-U
   PubMed Web of Science ®Google Scholar
• Romanowski EG, Yates KA, Gordon YJ. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections. Invest Ophthalmol Vis Sci. 2009;50:5295–5299. doi:10.1167/iovs.08-3286
   PubMed Web of Science ®Google Scholar
• Romanowski EG, Hussein ITM, Cardinale SC, et al. Filociclovir is an active antiviral agent against ocular adenovirus isolates in vitro and in the Ad5/NZW rabbit ocular model. Pharmaceuticals. 2021;15:294. doi:10.3390/ph14040294
   Web of Science ®Google Scholar
• Gordon YJ, Romanowski EG, Araullo-Cruz T, De Clercq E. Pre-treatment with topical 0.1% S-HPMPC inhibits adenovirus type 5 replication in the NZ rabbit ocular model. Cornea. 1992;11:529–533. doi:10.1097/00003226-199211000-00008
   PubMed Web of Science ®Google Scholar
• Gordon YJ, Romanowski EG, Topical A-CT. HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci. 1994;35:4135–4143.
   PubMed Web of Science ®Google Scholar
• Romanowski EG, Gordon YJ. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci. 2000;41:460–463.
   PubMed Web of Science ®Google Scholar
• Romanowski EG, Yates KA, Teuchner B, Nagl M, Irschick EU, Gordon YJ. N–Chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model. Invest Ophthalmol Vis Sci. 2006;47:2021–2026.
   PubMed Web of Science ®Google Scholar
• Nwanegbo EC, Romanowski EG, Gordon YJ, Gambotto A. Efficacy of topical immunoglobulins (IG) against experimental adenoviral ocular infection. Invest Ophthalmol Vis Sci. 2007;48:4171–4176. doi:10.1167/iovs.07-0491
   PubMed Web of Science ®Google Scholar
• Romanowski EG, Yates KA, Paull JRA, Heery GP, Shanks RMQ. Topical astodrimer sodium, a non-toxic polyanionic dendrimer, demonstrates antiviral activity in an experimental ocular adenovirus infection model. Molecules. 2021;26:3419. doi:10.3390/molecules26113419
   Web of Science ®Google Scholar
• Napoli PE, Mangoni L, Gentile P, Braghiroli M, Fossarello M. A panel of broad-spectrum antivirals in topical ophthalmic medications from the drug repurposing approach during and after the coronavirus disease 2019 era. J Clin Med. 2020;9:2441. doi:10.3390/jcm9082441
   PubMed Web of Science ®Google Scholar
• Isenberg SJ, Apt L, Valenton M, et al. A Controlled Trial of Povidone–Iodine to Treat Infectious Conjunctivitis in Children. Am J Ophthalmol. 2002;134:681–688. doi:10.1016/S0002-9394(02)01701-4
   PubMed Web of Science ®Google Scholar
• Sauerbrei A, Sehr K, Brandstädt A, et al. Sensitivity of human adenoviruses to different groups of chemical biocides. J Hosp Infect. 2004;57:59–66. doi:10.1016/j.jhin.2004.01.022
   PubMed Web of Science ®Google Scholar
• Monnerat N, Bossart W, Thiel MA. Povidone-iodine for treatment of adenoviral conjunctivitis: an in vitro study. Klin Monatsbl Augenheilkd. 2006;223:349–352. doi:10.1055/s-2006-926633
   PubMed Web of Science ®Google Scholar
• Rutala WA, Peacock JE, Gergen MF, Sobsey MD, Weber DJ. Efficacy of hospital germicides against adenovirus 8, a common cause of epidemic keratoconjunctivitis in health care facilities. Antimicrob Agents Chemother. 2006;50:1419–1424. doi:10.1128/AAC.50.4.1419-1424.2006
   PubMed Web of Science ®Google Scholar
• Pelletier JS, Stewart K, Trattler W, et al. A combination povidone-iodine 0.4%/dexamethasone 0.1% ophthalmic suspension in the treatment of adenoviral conjunctivitis. Adv Ther. 2009;26:776–783. doi:10.1007/s12325-009-0062-1
   PubMed Web of Science ®Google Scholar
• Clement C, Capriotti JA, Kumar M, et al. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis. Invest Ophthalmol Vis Sci. 2011;52:339–344. doi:10.1167/iovs.10-5944
   PubMed Web of Science ®Google Scholar
• Trinavarat A, Atchaneeyasakul L. Treatment of epidemic keratoconjunctivitis with 2% povidone-iodine: a pilot study. J Ocul Pharmacol Ther. 2012;28:53–58. doi:10.1089/jop.2011.0082
   PubMed Web of Science ®Google Scholar
• Yates KA, Shanks RMQ, Kowalski RP, Romanowski EG. The in vitro evaluation of povidone-iodine against multiple ocular adenoviral types. J Oc Pharm Ther. 2019;35:132–136. doi:10.1089/jop.2018.0122
   PubMed Web of Science ®Google Scholar
• Wood A, Payne D. The action of three antiseptics/disinfectants against enveloped and non-enveloped viruses. J Hosp Infect. 1998;38:283–295. doi:10.1016/S0195-6701(98)90077-9
   PubMed Web of Science ®Google Scholar
• Béleca L, Tevi-Benissana C, Bianchic A, et al. In vitro inactivation of Chlamydia trachomatis and of a panel of DNA (HSV-2, CMV, adenovirus, BK virus) and RNA (RSV, enterovirus) viruses by the spermicide benzalkonium chloride. J Antimicrob Chemother. 2000;46:685–693. doi:10.1093/jac/46.5.685
   Web of Science ®Google Scholar
• Romanowski EG, Yates KA, Shanks RMQ, Kowalski RP. Benzalkonium chloride demonstrates concentration dependent antiviral activity against adenovirus in vitro. J Oc Pharm Ther. 2019;35:311–314. doi:10.1089/jop.2018.0145
   Web of Science ®Google Scholar
• Romanowski EG, Yates KA, O’Connor KE, Mah FS, Shanks RMQ, Kowalski RP. The evaluation of polyhexamethylene biguanide (PHMB) as a disinfectant for adenovirus. JAMA Ophthalmol. 2013;131:495–498. doi:10.1001/jamaophthalmol.2013.2498
   PubMed Web of Science ®Google Scholar
• Morfin F, Dupuis-Girod S, Mundweiler S, et al. In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antivir Ther. 2005;10:225–229.
   PubMed Web of Science ®Google Scholar
• Lee CS, Lee AY, Akileswaran L, et al. BAYnovation Study Group. Determinants of outcomes of adenoviral keratoconjunctivitis. Ophthalmology. 2018;125(9):1344–1353. doi:10.1016/j.ophtha.2018.02.016
   Web of Science ®Google Scholar
• Romanowski EG, Mah FS, Yates KA, Kowalski RP, Gordon YJ. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar® (Gatifloxacin 0.3%) in a NZW Rabbit Model. Am J Ophthalmol. 2005;139:867–877. doi:10.1016/j.ajo.2005.01.021
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Romanowski EG, Mah FS, Shanks RMQ, Gordon YJ. Topical levofloxacin 1.5% overcomes in vitro resistance in rabbit keratitis models. Acta Ophthalmol. 2010;88:e120–125. doi:10.1111/j.1755-3768.2010.01897.x
   PubMed Web of Science ®Google Scholar
• Kowalski RP, Romanowski EG, Yates KA, Romanowski JE, Grewal A, Bilonick RA. Is there a role for topical penicillin treatment of Staphylococcus aureus keratitis based on elevated corneal concentrations? J Clin Ophthalmol Optom. 2018;2:103.
   Google Scholar
• Romanowski JE, Romanowski EG, Yates KA, Kowalski RP. The successful treatment of experimental methicillin-resistant Staphylococcus aureus (MRSA) keratitis with topical penicillin. Ophthalmol Res Rep. 2018;3:ORRT–128.
   Google Scholar